AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright

Stock News

09/01

H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a "Buy" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.

Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1183251394"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183251394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183251394?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183251394","market":"us","top_or_hot":-1,"title":"AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright","media":"Stock News","content":"<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-01 14:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"創新藥","start_time":0,"source_url":"","article_id":"1183251394","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183251394","pubTimestamp":1756707626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SMMT":"Summit Therapeutics PLC","BK1161":"生物科技","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","06978":"永泰生物-B","BK4139":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","09926":"康方生物","LU1720050803.USD":"安联全方位中国股票基金","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC"},"translate_title":"康方生物的创新药物优势促使合作伙伴Summit Therapeutics(SMMT.US)H.C.将目标价上调至50美元。温赖特","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"09926":1,"SMMT":1},"content_text":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.\nSummit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}